Healixa Inc.
EMOR · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 2.81 | 3.12 | -0.07 |
| FCF Yield | -0.81% | -1.53% | -0.25% | -0.13% |
| EV / EBITDA | -18.15 | -279.00 | -278.16 | -83.95 |
| Quality | ||||
| ROIC | 189.50% | 10.51% | 97.55% | -4.54% |
| Gross Margin | 35.20% | -275.29% | 0.00% | -83.31% |
| Cash Conversion Ratio | 0.13 | 3.31 | 0.60 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -47.06% | -100.00% | 106.78% |
| Free Cash Flow Growth | 58.89% | -18.26% | -9.15% | -33.76% |
| Safety | ||||
| Net Debt / EBITDA | -1.03 | -10.69 | -1.19 | -0.02 |
| Interest Coverage | -16.71 | -1.01 | -11.71 | -272.94 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -429.84 | -13,608.19 | -6,797.86 | -369.88 |